A phase 2 trial showed that Trodelvy plus Keytruda had a high response rate with lasting responses, emphasizing “potential additive or synergistic effects,” an expert said.
2023 Fourth-Quarter reported sales growth of 7.3% to $21.4 Billion with operational growth of 7.2% and adjusted operational growth of 5.7% . Operational growth excluding COVID-19 Vaccine of.
A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.